President Donald Trump speech today: Fact-checking State of the Union, or SOTU 2026, address

In his State of the Union, President Trump made broad economic and policy claims that ABC News fact-checked: border encounters fell from over 1.5 million in 2024 to roughly 28,000 in 2025 but were not zero; headline inflation cited fell from about 3.0% to 2.4%; energy prices rose 6.3% (Jan 2025–Jan 2026) and ground coffee prices are up 34% year-over-year amid tariff effects. The White House’s claim of $9.6 trillion in investments contrasts with the president’s unsupported $18 trillion assertion, and drug-price moves have produced targeted cash-price cuts for some medicines (e.g., Wegovy, Zepbound) while larger list-price reductions for drugs such as Eliquis (~50%) and Jardiance (~66%) are largely tied to prior policies like Medicare negotiation.

Analysis

Market structure: Trump’s mix of tariffs, immigration enforcement and headline geopolitics reallocates profits toward domestic capital owners — domestic heavy industry, defense (RTX, LMT), energy (XOM/CVX) and data-center operators (EQIX, DLR) see pricing power; import-dependent retailers and consumer-goods makers (TGT, SBUX, PG) face margin pressure from higher input and food/coffee costs. Lower headline inflation (2.4%) supports longer-duration assets but is heterogeneous—energy and specific foodstuffs are rising, implying stagflation-like dispersion across sectors over 3–12 months.

Risk assessment: Tail risks include a sharp oil shock from Iran escalation (Brent +20%+ in 1–3 months), abrupt tariff/legal reversals that re-open supply chains, or a midterm political swing that changes regulatory plans. Immediate (days) volatility will be SOTU/CPI-driven, short-term (weeks–months) earnings-margin re-pricing, and long-term (quarters) realization of the $9.6–$18T investment claims; watch CPI, 10y yield moves >30bp, and Senate/House control polls as catalysts.

Trade implications: Favor convex trades—long duration treasuries (TLT) if 10y yield drops 30–50bp over 3–6 months, hedge equities with 3-month 5% OTM S&P puts ahead of midterms, and run relative-value: long COST vs short TGT for 3–9 months to capture pricing/membership resilience. Commodity/energy: establish tactical 3–6% long in XOM/CVX or Brent futures as a hedge for geopolitical oil upside; size small given political uncertainty.

Contrarian angles: Consensus understates persistent tariff-driven input-cost inflation and AI/data-center energy intensity; markets may be too complacent on CPI reacceleration risk (a 0.3–0.6% monthly CPI bump would reprice yields by 30–60bp). Historical parallel: 2018 tariff cycle compressed retailer multiples for 6–18 months — similar dispersion and pair-trade opportunities are likely now.

Key Decisions for Investors

• Establish a 2–3% portfolio long in TLT (or equivalent 10y futures) with target +4–6% price gain if 10y yield falls 30–50bp within 3–6 months; stop-loss if yield rises >25bp from entry.
• Implement a 2% long COST (Costco, ticker COST) vs 2% short TGT (Target, ticker TGT) pair trade for 3–9 months to capture margin/price-power divergence from tariffs; rebalance if TGT outperforms by >5% or margin guidance changes.
• Allocate 1.5–3% tactical long to XOM or CVX for 3–6 months as geopolitical oil insurance; trim if Brent drops below $75/bbl for a sustained 4-week period or rally exceeds +25%.
• Buy a 3-month 5% OTM S&P 500 put (size 1–3% portfolio notional) ahead of midterms/SOTU to hedge headline-driven downside; roll or liquidate after midterm results and two consecutive CPI prints under 0.2% MoM.
• Initiate a 1–2% long position in Eli Lilly (LLY) via a 6-month call spread (buy near-the-money, sell 20–30% OTM) to play weight-loss drug secular demand while capping pharma-policy risk; monitor Medicare negotiation updates monthly and cut if CMS announces binding price caps.